Ergot derivatives Bromocriptine

Bromocriptine Ergot derivative potent agonist at D2 receptors more toxic than pramipexole or ropinirole... 

The answer is d. (Hardman, pp 1371-13720 High prolactin levels in the serum result in amenorrhea, for reasons that are not known. Bromocriptine inhibits prolactin secretion through its dopaminergic action This compound, a semisynthetic ergot derivative, appears to be a dopamine receptor agonist. It is administered orally to the patient and, in most cases, menses occurs after a month of therapy. 

Dopamine receptor agonists. Deficient dopaminergic transmission in the striatum can be compensated by ergot derivatives (bromocriptine p. 114], lisu-ride, cabergoline, and pergolide) and nonergot compounds (ropinirole, prami-pexole). These agonists stimulate dopamine receptors (D2, D3, and D sub-types), have lower clinical efficacy than levodopa, and share its main adverse effects. 

At least as effective as bromocriptine in the treatment of advanced parkinsonian patients with levodopa-related motor fluctuations adverse effects similar in incidence and severity appears to lack some of the toxicity seen with bromocriptine, pergolide, and cabergoline (e.g., pleuropulmonary disease) may be a useful alternative in patients with intolerable adverse effects due to ergot derivatives... 

Bromocriptine, pergolide Ergot derivatives used in Parkinson s disease (see Chapter 28) and prolactinoma (see Chapter 37) ... 

Postural hypotension may occur, particularly at the initiation of therapy. Painless digital vasospasm is a dose-related complication of long-term treatment with the ergot derivatives (bromocriptine or pergolide). When cardiac arrhythmias occur, they are an indication for discontinuing treatment. Peripheral edema is sometimes problematic. Cardiac valvulopathy may occur with pergolide. 

Ergot derivatives. The first and most widely prescribed ergot derivative with dopaminomimetic properties is bromocriptine. Congeners of bromocriptine that are currently undergoing clinical evaluation include lysuride, pergolide, and CU 32-085 ... 

Other D-2 agonists ergot derivatives inhibit the D-1 receptor these include bromocriptine, lysuride, and CU32-085- The commoner adverse reactions induced by DA agonists comprise nausea, hypotension, dyskinesia, hallucinations and delusions. 

Terguride is an ergot derivative, a partial dopamine agonist with properties similar to those of bromocriptine. It has been used in the treatment of Parkinson s disease and hyperprolactinaemia. 

---